Prestige Consumer Healthcare Inc. Files 2024 Annual Report

TL;DR

<b>Prestige Consumer Healthcare Inc. has filed its annual 10-K report for the fiscal year ending March 31, 2024.</b>

AI Summary

Prestige Consumer Healthcare Inc. (PBH) filed a Annual Report (10-K) with the SEC on May 15, 2024. Prestige Consumer Healthcare Inc. filed its 10-K report for the fiscal year ending March 31, 2024. The company's principal business is in Pharmaceutical Preparations (SIC 2834). The filing covers the period from April 1, 2023, to March 31, 2024. The company was formerly known as Prestige Brands Holdings, Inc. and Prestige Household Brands, Inc. The filing address is 660 White Plains Rd., Tarrytown, NY 10591.

Why It Matters

For investors and stakeholders tracking Prestige Consumer Healthcare Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of the company's financial performance, business operations, and risk factors for the fiscal year 2024. Investors and analysts can use this report to assess the company's financial health, strategic direction, and potential future performance.

Risk Assessment

Risk Level: low — Prestige Consumer Healthcare Inc. shows low risk based on this filing. The risk is low as this is a standard annual filing with no immediate red flags indicated in the provided header information.

Analyst Insight

Review the full 10-K filing for detailed financial statements, management discussion, and risk factor analysis to understand Prestige Consumer Healthcare Inc.'s performance and outlook.

Key Numbers

• 2024-03-31 — Fiscal Year End (Conformed period of report)
• 2024-05-15 — Filing Date (As of date)
• 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)

Key Players & Entities

• Prestige Consumer Healthcare Inc. (company) — Filer name
• PBH (company) — Ticker symbol
• 2024-03-31 (date) — Fiscal year end
• 2024-05-15 (date) — Filing date
• 660 White Plains Rd. (address) — Business address
• Tarrytown (location) — Business address city
• NY (location) — Business address state
• 10591 (postal_code) — Business address zip

FAQ

Industry Context

Prestige Consumer Healthcare Inc. operates within the Pharmaceutical Preparations industry.

Regulatory Implications

The filing is made under the Securities Exchange Act of 1934.

What Investors Should Do

1. Analyze the detailed financial statements within the 10-K for revenue, net income, and other key financial metrics.
2. Examine the 'Risk Factors' section to understand potential challenges and threats to the company's business.
3. Review the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' for insights into the company's performance drivers.

Key Dates

• 2024-03-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-05-15: Filing Date — Date the 10-K report was officially filed with the SEC.

Year-Over-Year Comparison

This is the initial header information for the 2024 10-K filing; comparative data from the previous filing is not available in this snippet.

Key Financial Figures

• $0.01 — ich registered Common stock, par value $0.01 per share PBH New York Stock Exchange

Filing Documents

• pbh-20240331.htm (10-K) — 2322KB
• exhibit1026-agreementforre.htm (EX-10.26) — 43KB
• exhibit1027-agreementforpe.htm (EX-10.27) — 63KB
• exhibit191-pbhinsidertradi.htm (EX-19.1) — 69KB
• exhibit211directindirectsu.htm (EX-21.1) — 17KB
• pbhconsentfy24.htm (EX-23.1) — 1KB
• exhibit311certification_lo.htm (EX-31.1) — 16KB
• exhibit312certification_sa.htm (EX-31.2) — 16KB
• exhibit321certificationofe.htm (EX-32.1) — 8KB
• exhibit322certificationofc.htm (EX-32.2) — 8KB
• exhibit971-pbhclawbackpoli.htm (EX-97.1) — 49KB
• image_0.jpg (GRAPHIC) — 3KB
• pbh-20240331_g1.jpg (GRAPHIC) — 65KB
• pbh-20240331_g2.jpg (GRAPHIC) — 170KB
• pbhconsentfy24001.jpg (GRAPHIC) — 58KB
• 0001295947-24-000017.txt (&nbsp;) — 14029KB
• pbh-20240331.xsd (EX-101.SCH) — 88KB
• pbh-20240331_cal.xml (EX-101.CAL) — 164KB
• pbh-20240331_def.xml (EX-101.DEF) — 419KB
• pbh-20240331_lab.xml (EX-101.LAB) — 1056KB
• pbh-20240331_pre.xml (EX-101.PRE) — 786KB
• pbh-20240331_htm.xml (XML) — 2206KB

Risk Factors 13

Item 1A. Risk Factors 13

Unresolved Staff Comments 25

Item 1B. Unresolved Staff Comments 25

Cybersecurity 25

Item 1C. Cybersecurity 25

Properties 26

Item 2. Properties 26

Legal Proceedings 27

Item 3. Legal Proceedings 27

Mine Safety Disclosures 27

Item 4. Mine Safety Disclosures 27 Part II

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 28

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 28

(Reserved) 31

Item 6. (Reserved) 31

Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures About Market Risk 44

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 44

Financial Statements and Supplementary Data 46

Item 8. Financial Statements and Supplementary Data 46

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 85

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 85

Controls and Procedures 85

Item 9A. Controls and Procedures 85

Other Information 85

Item 9B. Other Information 85

Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 85

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 85 Part III

Directors, Executive Officers and Corporate Governance 86

Item 10. Directors, Executive Officers and Corporate Governance 86

Executive Compensation 86

Item 11. Executive Compensation 86

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 86

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 86

Certain Relationships and Related Transactions, and Director Independence 86

Item 13. Certain Relationships and Related Transactions, and Director Independence 86

Principal Accounting Fees and Services 86

Item 14. Principal Accounting Fees and Services 86 Part IV

Exhibits, Financial Statement Schedules 87

Item 15. Exhibits, Financial Statement Schedules 87

Form 10-K Summary 89

Item 16. Form 10-K Summary 89 TRADEMARKS AND TRADENAMES Trademarks and tradenames used in this Annual Report on Form 10-K are the property of Prestige Consumer Healthcare Inc. or its subsidiaries, as the case may be. We have italicized our trademarks or tradenames when they appear in this Annual Report on Form 10-K. Part I. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operations. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the "safe harbor" provisions of the PSLRA. Forward-looking statements speak only as of the date of this Annual Report on Form 10-K. Except as required under federal securities laws and the rules and regulations of the SEC, we do not intend to update any forward-looking statements to reflect events or circumstances arising after the date of this Annual Report on Form 10-K, whether as a result of new information, future events or otherwise. As a result of the risks and uncertainties described below, readers are cautioned not to place undue reliance on forward-looking statements included in this Annual Report on Form 10-K or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements. These forward-looking statements generally can be identified by the use of words or phrases such as "believe," "anticipate," "expect," "estimate," "plan," "project," "intend," "strategy," "goal," "objective," "continue," "future," "seek," "may," "might," "should," "would," "will," "will be," or other similar words and phrases. Forward-looking statements a

BUSINESS

ITEM 1. BUSINESS Overview Unless otherwise indicated by the context, all references in this Annual Report on Form 10-K to "we," "us," "our," the "Company" or "Prestige" refer to Prestige Consumer Healthcare Inc. and our subsidiaries. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc. Reference to a year (e.g., "2024") refers to our fiscal year ended March 31 of that year. We formed as a Delaware corporation in 1996 and are engaged in the development, manufacturing, marketing, sales and distribution of well-recognized, brand name, over-the-counter ("OTC") health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. We use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team to our competitive advantage. Our ultimate success is dependent on several factors, including our ability to: Develop and execute effective sales, advertising and marketing programs to maintain or grow our market share versus competitors over time; Establish and maintain our internal and third-party manufacturing and distribution relationships to fulfill customer demands; Develop innovative new products; Continue to grow our presence in the United States and international markets through acquisitions and organic growth; and Allocate capital effectively. We have grown our product portfolio both organically and through acquisitions. We develop our existing brands by investing in new product lines, brand extensions and strong advertising support. Acquisitions of consumer health and personal care brands have also been an important part of our growth strategy. We pursue this growth following an acquisition through spending on advertising and marketing support, new sales and marketing strategies, improved pa

View Full Filing

View this 10-K filing on SEC EDGAR